Management of Ventricular Tachycardia

Initial Assessment

The European Society of Cardiology recommends assessing hemodynamic stability first, then monitoring closely, obtaining a 12-lead ECG, evaluating for underlying causes, and considering cardiology consultation if the patient has structural heart disease or symptoms 1, 2
Determine if the patient is hemodynamically stable by assessing blood pressure, mental status, signs of hypoperfusion, according to the European Heart Journal 1, 3
Obtain a 12-lead ECG to document the rhythm and evaluate for underlying ischemia or structural abnormalities, as recommended by the European Heart Journal 1, 2
Assess oxygen saturation and provide supplemental oxygen if needed, as suggested by Circulation 3
Establish IV access for potential medication administration, according to Circulation 3

A 6-beat run of VT is considered non-sustained ventricular tachycardia (NSVT) as it lasts less than 30 seconds, according to the European Heart Journal 4
Monitor the patient closely for recurrence or progression to sustained VT, as recommended by the European Heart Journal 1, 5
Evaluate and correct potential triggers, including checking and correcting electrolyte abnormalities, particularly potassium and magnesium, as suggested by the European Heart Journal and the Journal of the American College of Cardiology 4, 6
Assess for myocardial ischemia with cardiac enzymes, according to the European Heart Journal 4, 7

Prepare for immediate synchronized cardioversion starting at 100-200 J, as recommended by the European Heart Journal and Circulation 1, 3
Provide appropriate sedation if the patient is conscious, according to the European Heart Journal 1
Have resuscitation equipment readily available, as suggested by the European Heart Journal 5

For recurrent episodes in hemodynamically stable patients, consider IV beta-blockers if no contraindications exist, especially if ischemia is suspected, as recommended by the European Heart Journal 7
IV amiodarone may be considered for frequent recurrences, according to the Journal of the American College of Cardiology 6
IV procainamide can be considered in patients without heart failure or acute MI, as suggested by Circulation and the Journal of the American College of Cardiology 3, 6

Evaluate for coronary artery disease if clinically indicated, according to the European Heart Journal 4, 7
Consider cardiac monitoring for 24-48 hours to detect additional arrhythmias, as recommended by the European Heart Journal 1

If NSVT occurs in the setting of structural heart disease, particularly with reduced ejection fraction, the European Heart Journal recommends cardiology consultation 4, 7
For patients with recurrent symptomatic episodes, consider electrophysiology consultation for risk stratification, as suggested by the European Heart Journal 4, 7
Evaluate for ICD if patient has significant structural heart disease, particularly with reduced ejection fraction, according to the European Heart Journal 4, 7

Avoid class IC antiarrhythmic drugs in patients with history of myocardial infarction, as recommended by the European Heart Journal 7
Don't treat isolated ventricular premature beats or non-sustained VT with antiarrhythmic drugs in asymptomatic patients without structural heart disease, according to the European Heart Journal and the Journal of the American College of Cardiology 4, 6

The American College of Cardiology recommends beta-blockers as the first-line pharmacological therapy for primary prevention of sudden cardiac death in patients with coronary artery disease and NSVT, with amiodarone as an adjunctive therapy option 8
For patients with idiopathic dilated cardiomyopathy and NSVT, the American College of Cardiology recommends ICD therapy for primary prevention when LVEF ≤30-35%, NYHA class II-III, and on optimal medical therapy, with beta-blockers and/or amiodarone as pharmacological adjuncts 8
The American College of Cardiology suggests amiodarone, sotalol, and/or beta-blockers to suppress symptomatic ventricular tachyarrhythmias in heart failure patients, serving as adjuncts to ICD therapy in optimally treated patients 8
IV procainamide can be considered in patients without heart failure or acute MI for recurrent symptomatic NSVT in stable patients 9